Assembly Biosciences Inc
ASMB18.385USD
-0.015-0.08%
Market hours （ET）Quotes delayed by 15 min
140.07MMarket Cap
LossP/E TTM
More Details of Assembly Biosciences Inc Company
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Company Info
Ticker SymbolASMB
Company nameAssembly Biosciences Inc
IPO dateDec 17, 2010
CEO- -
Number of employees73
Security typeOrdinary Share
Fiscal year-endDec 17
AddressTwo Tower Place
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone18334094583
Websitehttps://www.assemblybio.com/
Ticker SymbolASMB
IPO dateDec 17, 2010
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Ms. Gina Consylman, CPA
Ms. Gina Consylman, CPA
Independent Director
Independent Director
--
--
Dr. Tomas Cihlar, Ph.D.
Dr. Tomas Cihlar, Ph.D.
Director
Director
--
--
Mr. Robert D. Cook, II
Mr. Robert D. Cook, II
Director
Director
--
--
Dr. William E. Delaney, IV, Ph.D.
Dr. William E. Delaney, IV, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jun 14
Updated: Sat, Jun 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
28.93%
Schornstein (Alexander)
9.53%
The Vanguard Group, Inc.
2.83%
B Group, Inc.
2.62%
Renaissance Technologies LLC
1.48%
Other
54.61%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
28.93%
Schornstein (Alexander)
9.53%
The Vanguard Group, Inc.
2.83%
B Group, Inc.
2.62%
Renaissance Technologies LLC
1.48%
Other
54.61%
Shareholder Types
Shareholders
Proportion
Corporation
28.93%
Individual Investor
10.37%
Investment Advisor
7.95%
Investment Advisor/Hedge Fund
2.83%
Hedge Fund
2.16%
Research Firm
0.04%
Pension Fund
0.03%
Other
47.69%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
95
4.00M
52.31%
-445.87K
2025Q1
96
3.96M
52.03%
-545.18K
2024Q4
98
3.98M
62.54%
+317.06K
2024Q3
100
3.09M
48.81%
-530.17K
2024Q2
100
3.18M
50.27%
+64.71K
2024Q1
106
2.47M
41.54%
+268.64K
2023Q4
118
2.50M
200.35%
+260.11K
2023Q3
132
888.05K
20.29%
-1.13M
2023Q2
155
960.87K
22.02%
-1.33M
2023Q1
204
1.08M
24.92%
-1.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
2.21M
28.93%
--
--
Mar 31, 2025
Schornstein (Alexander)
728.11K
9.53%
-44.00K
-5.70%
Dec 19, 2024
The Vanguard Group, Inc.
215.98K
2.83%
+15.53K
+7.74%
Mar 31, 2025
B Group, Inc.
200.00K
2.62%
+149.35K
+294.86%
Mar 31, 2025
Renaissance Technologies LLC
113.31K
1.48%
+18.60K
+19.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
71.97K
0.94%
-484.00
-0.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
47.70K
0.62%
+1.07K
+2.29%
Mar 31, 2025
Monimus Capital Management, LP
42.07K
0.55%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
28.32K
0.37%
-326.00
-1.14%
Mar 31, 2025
Federated MDTA LLC
25.39K
0.33%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Fidelity Enhanced Small Cap ETF
0%
Avantis US Small Cap Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Fidelity Enhanced Small Cap ETF
Proportion0%
Avantis US Small Cap Value ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
Date
Type
Ratio
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
Feb 08, 2024
Merger
12<1
